Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reina Watanabe

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
International Journal of Hematology|February 19, 2011
Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignanciesTakayoshi Tachibana, Masatsugu Tanaka, Hirotaka Takasaki, et al.
International Journal of Hematology|January 22, 2010
Serum HO-1 is useful to make differential diagnosis of secondary hemophagocytic syndrome from other similar hematological conditionsTakuya Miyazaki, Yohei Kirino, Mitsuhiro Takeno, et al.
Leukemia Research|August 10, 2013
Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneReina Watanabe, Naoto Tomita, Kumiko Kishimoto, et al.
Medical Oncology (Northwood, London, England)|August 22, 2014
Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapyYuki Nakajima, Naoto Tomita, Reina Watanabe, et al.
European Journal of Haematology|November 29, 2013
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab eraReina Watanabe, Naoto Tomita, Megumi Itabashi, et al.
Leukemia Research|December 27, 2014
Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapyYuki Nakajima, Naoto Tomita, Megumi Itabashi, et al.
Leukemia & Lymphoma|June 11, 2014
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisoneNaoto Tomita, Hirotaka Takasaki, Yasufumi Ishiyama, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 15, 2015
[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy]Hideyuki Koharazawa, Reina Watanabe, Yukako Hattori, et al.
Cancer Science|November 3, 2011
Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab eraNaoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, et al.
Leukemia & Lymphoma|June 9, 2017
The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxisNaoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
International Journal of Hematology|February 19, 2011
Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignanciesTakayoshi Tachibana, Masatsugu Tanaka, Hirotaka Takasaki, et al.
International Journal of Hematology|January 22, 2010
Serum HO-1 is useful to make differential diagnosis of secondary hemophagocytic syndrome from other similar hematological conditionsTakuya Miyazaki, Yohei Kirino, Mitsuhiro Takeno, et al.
Leukemia Research|August 10, 2013
Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneReina Watanabe, Naoto Tomita, Kumiko Kishimoto, et al.
Medical Oncology (Northwood, London, England)|August 22, 2014
Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapyYuki Nakajima, Naoto Tomita, Reina Watanabe, et al.
European Journal of Haematology|November 29, 2013
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab eraReina Watanabe, Naoto Tomita, Megumi Itabashi, et al.
Leukemia Research|December 27, 2014
Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapyYuki Nakajima, Naoto Tomita, Megumi Itabashi, et al.
Leukemia & Lymphoma|June 11, 2014
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisoneNaoto Tomita, Hirotaka Takasaki, Yasufumi Ishiyama, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 15, 2015
[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy]Hideyuki Koharazawa, Reina Watanabe, Yukako Hattori, et al.
Cancer Science|November 3, 2011
Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab eraNaoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, et al.
Leukemia & Lymphoma|June 9, 2017
The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxisNaoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, et al.
Pageof 3